News
Dupixent approved in EU for atopic dermatitis in children
The European Commission has approved Sanofi and Regeneron’s biologic treatment Dupixent for the treatment of children aged six to 11 years with severe atopic dermatitis.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Commission has approved Sanofi and Regeneron’s biologic treatment Dupixent for the treatment of children aged six to 11 years with severe atopic dermatitis.